"The best way to predict the future is to invent it."
Alan Kay
"Because pharmaceutical development is a complex environment with strict rules that aim to protect patients from potential hazards of drugs, our team combines expertise in immuno-oncology research, therapeutic innovation, clinical pharmacology, medicinal chemistry, radiotherapy, medical oncology, clinical trials, regulatory affairs and drug development"
Executive Committee
Meet the founders
Guillaume Brion, MD
Chief Executive Officer
Guillaume Brion is a co-founder of Findimmune and serves as President and Chief Executive Officer.
Since 1988 he has founded, developed and managed service companies in the field of clinical development for the pharmaceutical industry. He gained broad experience in setting-up and managing more than 200 clinical trials from first human administration to large multi-centre, multi-national pivotal clinical trials at GRES (Groupe de Recherche et d’Etudes Scientifiques), TARS (Travaux Analyses Recherches Scientifiques), Versus Clinical Research Services and Farma Research, all CROs dedicated to early clinical development. He has held business development positions at UCTi (Unilabs Clinical Trials) and MCBio (Merieux Centralized Biology), both central laboratory service companies. He has been a clinical study investigator in the HIV vaccine research program at European Georges Pompidou Hospital in the Clinical Immunology Department of Prof. Michel Kazatchkine before becoming Clinical Research Physician and Medical Analyst of Business Development at Orphan Europe, the Rare Diseases Business Unit of Recordati Group. He is the co-founder of MedDay Pharmaceuticals SA where he held the position of Chairman and CEO, then COO, managing 5 affiliates and 70 FTEs.
Guillaume holds an M.D. from the University of René Descartes, Paris.
Prof. Eric Deutsch, MD, PhD
Chief Molecular Radiotherapy Research
Eric Deutsch is a co-founder of Findimmune
Eric Deutsch, MD, PhD, is full professor of oncology, specialty in radiotherapy, at the Paris-Saclay University.
He has more than 15 years experience in the field of preclinical and translational research in new drugs and radiotherapy and clinical trials. He is one of the stackeholders of the Early Clinical Trial Program of Gustave Roussy Cancer Campus, and runs several novel drug-radiotherapy clinical trials.
Altogether with Jean-Luc Perfettini, he leads the INSERM UMR-S 1030 “Molecular Radiotherapy and Innovative therapeutics” research unit and the Radiation Oncology Department of Gustave Roussy.
Prof. Angelo Paci, PharmD, PhD
Chief Medicinal Chemistry & Pharmacology Research
Angelo Paci is a co-founder of Findimmune.
Angelo Paci is Professor of Pharmacokinetics and onco-pharmacology in the School of Pharmacy at Paris Saclay University and Head of the Pharmacology Department at the Gustave Roussy Cancer Campus. He obtained his PhD in Medicinal chemistry and Pharmacology in 2000 from the University of Paris Descartes, France. He has more than 15 years experience in the field of drug design and nanodrug delivery (6 patents), and now he is member of the “Cell death, Immunity and Innovative Therapeutics” team at INSERM UMR-S 1030 "Molecular Radiotherapy and Innovative therapeutics". He has developed clinical pharmacology interests devoted to patients with onco-hematological malignancies since 2006, including studies of therapeutic drug monitoring and pharmacokinetics of anticancer drugs. He is author of more than 120 publications (including articles in Nat Com, J Clin Oncol and Cancer Discov). Besides his clinical and scientific activities, he obtained in 2012 a Master in Management and Health Economy at the ESSEC Business School in Paris. He is member of the French National Academy of Pharmacy since 2019.
Jean-Luc Perfettini, PhD
Chief Immunology Research
Jean-Luc Perfettini is a co-founder of Findimmune.
Jean-Luc Perfettini is currently “Director of Research” at the “French Medical Research Council” (INSERM), director of the research unit INSERM UMR-S 1030 “Molecular Radiotherapy and Innovative therapeutics” with Eric Deutsch, Director of the “Cell Death, Immunity and Innovative Therapeutics” team at Gustave Roussy Cancer Campus and member of the council of the Laboratory of Excellence in Research on Medication and Innovative Therapeutics (Labex LERMIT). Jean-Luc Perfettini earned his PhD in the fields of immunology, microbiology and cellular biology in the laboratories of Prof. David M. Ojcius, Prof. Alice Dautry and Prof. Philippe Kourilsky at the Pasteur Institute. He obtained his “Advanced Immunology” diploma at the Pasteur Institute in 1998 and then his PhD in Immunology from University of Paris Diderot in 2002. From 2002 to 2006, Jean-Luc Perfettini received post-doctoral training in Guido Kroemer’s laboratory. In 2006, Jean-Luc Perfettini became a senior scientist at INSERM in Guido Kroemer’s laboratory and obtained his accreditation to direct research in 2010. Since 2013, Jean-Luc Perfettini is “Director of Research” at INSERM, at the Gustave Roussy Cancer Campus and at Labex LERMIT. Jean-Luc Perfettini is also visiting professor at University of the Pacific (San Francisco). Jean-Luc Perfettini is currently developing an integrative research program, in the field of radiation oncology and innovative therapeutics that aims to (i) characterize anti-cancer treatment-induced cell death and senescence modalities and mechanisms of macrophage reprogramming, (ii) develop preclinical mouse models to study the immune responses elicited by anti-cancer treatments, and (iii) identify innovative therapeutic approaches using nano-medicine and cell therapy that could improve the effectiveness of anti-cancer treatments and immune-related diseases. Jean-Luc Perfettini is an internationally-recognized expert in the field of cell death processes and innate immunity (particularly with regards to their roles in microbial infection and cancer), and is author of more than 70 publications (including articles in Nat Immunol, Nat Med, Nat Cell Biol, J Exp Med and Cell Rep). He has also filed 14 patents related to predictive biomarkers in cancer, therapeutic innovation, and nano-medicine.